« Zurück
Startseite /
Anti-Human CD194 (CCR4) Mogamulizumab [Clone KW-0761] – Biotin - 100 µg

Anti-Human CD194 (CCR4) Mogamulizumab [Clone KW-0761] – Biotin - 100 µg

ArtNr	LEIN-LT1001-100ug
Hersteller	Leinco Technologies
Menge	100 ug
Kategorie	Oncology Antibodies By Cell Type Hematology Leukemia Lymphoma Flow Cytometry ELISA Primary Antibodies Immunostaining Functional Assays
Typ	Antibody Monoclonal
Applikationen	FC, ELISA, FA
Clon	KW-0761
Specific against	Human (Homo sapiens)
Host	Human
Citations	1. Yamamoto, K. et al. (2010) J Clin Oncol. 28(9):1591-8. 2. Mimura, Y. et al. (2018) Protein Cell 9(1):47-62. 3. Yamano, Y. et al. (2018) N Engl J Med 378 (6), 529-538.
NCBI	1233
ECLASS 10.1	42030590
ECLASS 11.0	42030590
UNSPSC	12352203
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Applications	Depletion, ELISA, FA, FC
Manufacturer - Category	Recombinant Antibodies>Biosimilar Recombinant Antibodies
Manufacturer - Targets	CD194
Country of Origin	USA
Shipping Temperature	Next Day 2 - 8°C
Storage Conditions	Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Product Description	Clone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.1 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1–infected cells and the levels of inflammatory markers related to HTLV-1–Associated Myelopathy.3
Background	Clone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.¹ CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1–infected cells and the levels of inflammatory markers related to HTLV-1–Associated Myelopathy.³
Additional Reported Applications For Relevant Conjugates	Depletion
Other Applications Reported In Literature	FA
PubMed	CD194
Manufacturer - Research Area	Biosimilars, Cancer, Immuno-Oncology, Immunology
Manufacturer - Expression host	HEK-293
Manufacturer - Specificity	This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mogamulizumab. Clone KW-0761 recognizes human CD194 (CCR4). This product is for research use only.
FC Effector Activity	Active
RRID	AB_2893875
Concentration	0.5 mg/ml
Formulation	This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Antigen Distribution	CCR4 is primarily expressed by Th2 and regulatory T cells in addition to expression on leukemic cells in cutaneous T-cell lymphoma (CTCL).
Immunogen	Humanization of mouse anti-CCR4 mAb7.
Regulatory Status	Research Use Only (RUO). Non-Therapeutic.
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords	CKR4; K5-5; CD194; CMKBR4; ChemR13; CC-CKR-4; HGCN:14099; biosimilar; leukemia

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

LEIN-LT1001-100ug-safety-datasheet.pdf